iX Biopharma Ltd. (SG:42C) has released an update.
iX Biopharma Ltd is capitalizing on the surging demand for GLP-1 drugs used in diabetes and obesity treatment with their novel sublingual semaglutide wafer, iXB 401, while leveraging their newly developed WaferlogiX technology. The company has also regained control over the licensing of Wafermine, a product for pain and depression, and is focusing on the commercialization and expansion of their anti-aging Healthspan product line, which includes sublingual NAD+ and Glutathione wafers.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
